Skip to main content

Advertisement

SpringerLink
Log in

Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders

  • Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Tumefactive demyelinating lesions are rare consequences of central nervous system (CNS) idiopathic inflammatory demyelinating diseases. Tumefactive demyelinating lesions pose a diagnostic challenge because they can mimic tumors and abscesses and because they can be caused by a heterogeneous range of disorders. This article reviews the recent literature on the clinical presentation; radiographic features; prognosis; and management of tumefactive demyelinating lesions in multiple sclerosis, acute demyelinating encephalomyelitis, neuromyelitis optica, and the rare variants of multiple sclerosis including Schilder’s disease, Marburg acute multiple sclerosis, and Balo’s concentric sclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interests, published recently, have been highlighted as: • Of importance •• Of major importance

  1. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–7.

    Article  CAS  PubMed  Google Scholar 

  2. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120:2059–69.

    Article  PubMed  Google Scholar 

  4. Suzuki M, Kawasaki H, Masaki K, et al. An autopsy case of the Marburg variant of multiple sclerosis (acute multiple sclerosis). Intern Med. 2013;52:1825–32.

    Article  PubMed  Google Scholar 

  5. Talab R, Kundrata Z. Marburg variant multiple sclerosis—a case report. Neuro Endocrinol Lett. 2011;32(4):415–20.

    PubMed  Google Scholar 

  6. Turatti M, Gajofatto A, Rossi F, et al. Long survival and clinical stability in Marburg’s variant multiple sclerosis. Neurol Sci. 2010;31(6):807–11.

    Article  PubMed  Google Scholar 

  7. Nozaki K, Abou-Fayssal N. High dose cyclophosphamide treatment in Marburg variant multiple sclerosis. A case report. J Neurol Sci. 2010;296(1–2):121–3.

    Article  CAS  PubMed  Google Scholar 

  8. Beniac DR, Wood DD, Palaniyar N, et al. Marburg’s variant of multiple sclerosis correlates with a less compact structure of myelin basic protein. Mol Cell Biol Res Commun. 1999;1:48–51.

    Article  CAS  PubMed  Google Scholar 

  9. Bitsch A, Wegener C, da Costa C, et al. Lesion development in Marburg’s type of acute multiple sclerosis: from inflammation to demyelination. Mult Scler. 1999;5:138–46.

    Article  CAS  PubMed  Google Scholar 

  10. Mehler MF, Rabinowich L. Inflammatory myelinoclastic diffuse sclerosis (Schilder’s disease): neuroradiographic findings. AJNR. 1989;10:176–80.

    CAS  PubMed  Google Scholar 

  11. Ferrer I, Pujol A. Schilder’s disease a heterogenous group of disorders known as X-linked adrenoleukodystrophy. Foreword. Brain Pathol. 2010;20(4):815–6.

    Article  PubMed  Google Scholar 

  12. Kraus D, Konen O, Straussberg R. Schilder’s disease: non-invasive diagnosis and successful treatment with human immunoglobulins. Eur J Paediatr Neurol. 2012;16(2):206–8.

    Article  PubMed  Google Scholar 

  13. Bacigaluppi S, Polonara G, Zavanone ML, et al. Schilder’s disease: non-invasive diagnosis?: a case report and review. Neurol Sci. 2009;30(5):421–30.

    Article  PubMed  Google Scholar 

  14. Poser CM, Goutieres F, Carpentier MA, Aicardi J. Schilder’s myelinoclastic diffuse sclerosis. Pediatrics. 1986;77:107–12. Erratum in: Pediatrics 1986 Jul;78(1):138.

    CAS  PubMed  Google Scholar 

  15. Balo J. Encephalitis periaxialis concentrica. Arch Neurol. 1928;19:242–63.

    Article  Google Scholar 

  16. Ng SH, Ko SF, Cheung YC, et al. MRI features of Baló’s concentric sclerosis. Brit J Radiol. 1999;72:400–3.

    Article  CAS  PubMed  Google Scholar 

  17. Darke M, Bahador FM, Miller DC, Litofsky NS, Ahsan H. Baló’s concentric sclerosis: imaging findings and pathological correlation. J Radiol Case Rep. 2013;7(6):1–8.

    PubMed Central  PubMed  Google Scholar 

  18. Hardy TA, Miller DH. Balo’s concentric sclerosis. Lancet Neurol. 2014;13:740–46.

    Article  PubMed  Google Scholar 

  19. Karaarslan E, Altintas A, Senol U, et al. Baló’s concentric sclerosis: clinical and radiologic features of five cases. Am J Neuroradiol. 2001;22:1362–7.

    CAS  PubMed  Google Scholar 

  20. Graber JJ, Kister I, Geyer H, et al. Neuromyelitis optica and concentric rings of Balo in the brainstem. Arch Neurol. 2009;66:274–5.

    PubMed  Google Scholar 

  21. Kishimoto R, Yabe I, Niino M, et al. Balo’s concentric sclerosis-like lesion in the brainstem of a multiple sclerosis patient. J Neurol. 2008;255:760–1.

    Article  PubMed  Google Scholar 

  22. Markiewicz D, Adamczewska-Goncerzewicz Z, et al. A case of primary form of progressive multifocal leukoencephalopathy with concentric demyelination of Balo type. Neuropatol Pol. 1977;15:491–500.

    CAS  PubMed  Google Scholar 

  23. Chitnis T, Hollmann TJ. CADASIL mutation and Balo concentric sclerosis: a link between demyelination and ischemia? Neurology. 2012;78:221–23.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Ferreira D, Castro S, Nadais G, et al. Demyelinating lesions with features of Balo’s concentric sclerosis in a patient with active hepatitis C and human herpes virus 6 infection. Eur J Neurol. 2011;18:e6–7.

    Article  CAS  PubMed  Google Scholar 

  25. Masdeu JC, Quinto C, Olivera C, et al. Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology. 2000;54:1427–33.

    Article  CAS  PubMed  Google Scholar 

  26. Poser S, Luer W, Bruhn H, et al. Acute demyelinating disease: classification and non-invasive diagnosis. Acta Neurol Scand. 1992;86:579–85.

    Article  CAS  PubMed  Google Scholar 

  27. Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008;131:1759–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Altintas A, Petek B, Isik N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler. 2012;18(10):1448–53. Study of 54 patients presenting radiographically with tumefactive demyelination. One of the largest, recent cohorts of patients.

    Article  CAS  PubMed  Google Scholar 

  29. Wallner-Blazek M, Rovira A, Fillipp M, et al. Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol. 2013;260:2016–22. Study of 90 patients with tumefactive demyelination diagnosed on MRI. Radiographic characteristics were analyzed in an effort to determine radiographic signs that may increase chance of conversion to MS. Also one of the largest recent cohorts of patients with tumefactive demyelination.

    Article  CAS  PubMed  Google Scholar 

  30. Morin MP, Patenaude Y, Sinsky AB, et al. Solitary tumefactive demyelinating lesions in children. J Child Neurol. 2011;26(8):995–9.

    Article  PubMed  Google Scholar 

  31. Takeuchi T, Ogura M, Sato M, et al. Late-onset tumefactive multiple sclerosis. Rad Med. 2008;26:549–52.

    Article  Google Scholar 

  32. Ketelslegers IA, Visser IER, Neuteboom RF, et al. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. Mult Scler J. 2010;17(4):441–8.

    Article  Google Scholar 

  33. Kobayashi M, Shimizu Y, Shibata N, et al. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology. J Neurol. 2014;261:1902–10.

    Article  CAS  PubMed  Google Scholar 

  34. Law M, Meltzer DE, Cha S. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. Neuroradiology. 2002;44:986–9.

    Article  CAS  PubMed  Google Scholar 

  35. Takenaka S, Shinoda J, Asano Y, et al. Metabolic assessment of monofocal acute inflammatory demyelination using MR spectroscopy and (11)C-methionine-, (11)C-choline-, and (18)F-fluorodeoxyglucose-PET. Brain Tumor Pathol. 2011;28:229–38.

    Article  CAS  PubMed  Google Scholar 

  36. Kim DS, Na DG, Kim KH, et al. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology. 2009;251:467–75.

    Article  PubMed  Google Scholar 

  37. Yamamoto J, Shimajiri S, Nakano Y, Nishizawa S. Primary central nervous system lymphoma with preceding spontaneous pseudotumoral demyelination in an immunocompetent adult patient: a case report and literature review. Oncol Lett. 2014;7(6):1835–8.

    PubMed Central  PubMed  Google Scholar 

  38. Sega S, Horvat A, Popovic M. Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases. Clin Neurol Neurosurg. 2006;108(3):259–65.

    Article  PubMed  Google Scholar 

  39. Golombievski EE, McCoyd MA, Lee JM, Schneck MJ. Biopsy proven tumefactive multiple sclerosis with concomitant glioma: case report and review of the literature. Front Neurol. 2015;6:150.

    PubMed Central  PubMed  Google Scholar 

  40. Annesley-Williams D, Farrell MA, Staunton H, Brett FM. Acute demyelination, neuropathological diagnosis, and clinical evolution. J Neuropath Exp Neurol. 2000;59:477–89.

    Article  CAS  PubMed  Google Scholar 

  41. Zagzag D, Miller DC, Kleinman GM, Abati A, et al. Demyelinating disease versus tumor in surgical neuropathology: clues to a correct pathological diagnosis. Am J Surg Path. 1993;17:537–45.

    Article  CAS  PubMed  Google Scholar 

  42. Di Patre PL, Castillo V, Delavelle J, et al. “Tumor-mimicking” multiple sclerosis. Clin Neuropath. 2003;22:235–9.

    Google Scholar 

  43. Jacquerye P, Ossemann M, Laloux P, et al. Acute fulminant multiple sclerosis and plasma exchange. Eur Neurol. 1999;41:174–5.

    Article  CAS  PubMed  Google Scholar 

  44. Weinshenker BG. Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. J Clin Apheresis. 1999;14:144–8.

    Article  CAS  PubMed  Google Scholar 

  45. Mao-Draayer Y, Braff S, Pendlebury W, Panitch H. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology. 2002;59:1074–7.

    Article  PubMed  Google Scholar 

  46. Fan X, Mahta A, De Jager PL, Kesari S. Rituximab for tumefactive inflammatory demyelination: a case report. Clin Neurol Neurosurg. 2012;114(10):1326–8.

    Article  PubMed  Google Scholar 

  47. Sempere AP, Feliu-Rey E, Sanchez-Perez R, Nieto-Navarro J. Neurological picture. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. J Neurol Neurosurg Psychiatry. 2013;84(12):1338–9.

    Article  PubMed  Google Scholar 

  48. Siffrin V, Müller-Forell W, von Pein H, Zipp F. How to treat tumefactive demyelinating disease? Mult Scler. 2014;20(5):631–3.

    Article  PubMed  Google Scholar 

  49. Ragel BT, Fassett DR, Baringer JR, et al. Decompressive hemicraniectomy for tumefactive demyelination with transtentorial herniation: observation. Surg Neurol. 2006;65:582–3.

    Article  PubMed  Google Scholar 

  50. Hardy TA, Chataway J. Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry. 2013;84(9):1047–53.

    Article  PubMed  Google Scholar 

  51. Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology. 2013;81(19):1654–8.

    Article  PubMed  Google Scholar 

  52. Boangher S, Goffette S, Van Pesch V, Mespouille P. Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy. Acta Neurol Belg. 2015 Jun 14. [Epub ahead of print]

  53. Hellmann MA, Lev N, Lotan I, et al. Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. J Neurol Sci. 2014;344(1–2):193–7.

    Article  CAS  PubMed  Google Scholar 

  54. Beume LA, Dersch R, Fuhrer H, Stich O, et al. Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab. J Clin Neurosci. 2015;22(2):400–1.

    Article  CAS  PubMed  Google Scholar 

  55. Nagappa M, Taly AB, Sinha S, et al. Tumefactive demyelination: clinical, imaging and follow-up observations in thirty-nine patients. Acta Neurol Scand. 2013;128(1):39–47.

    Article  CAS  PubMed  Google Scholar 

  56. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol. 1993;33:18–27.

    Article  CAS  PubMed  Google Scholar 

  57. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology. 2004;62:51–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L226, Portland, OR, 97239, USA

    Meredith C. Frederick & Michelle H. Cameron

  2. Multiple Sclerosis Center of Excellence-West, Veterans Affairs Portland Health Care System, Portland, OR, 97239, USA

    Meredith C. Frederick & Michelle H. Cameron

Authors
  1. Meredith C. Frederick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle H. Cameron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meredith C. Frederick.

Ethics declarations

Conflict of Interest

Meredith C. Frederick and Michelle H. Cameron declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Demyelinating Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frederick, M.C., Cameron, M.H. Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders. Curr Neurol Neurosci Rep 16, 26 (2016). https://doi.org/10.1007/s11910-016-0626-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-016-0626-9

Keywords

Search

Navigation